Fluvoxamine Use in Depression

Efficacy and Safety

• The American College of Physicians guidelines confirm that available evidence does not support clinically significant differences in efficacy, effectiveness, or quality of life among SSRIs for treatment of major depressive disorder 1, 2, 3, 4
• Approximately 62% of patients achieve treatment response during 6-12 weeks of treatment with second-generation antidepressants, with 46% achieving remission 2, 4

Pharmacokinetic and Drug Interaction Considerations

• Fluvoxamine is a potent inhibitor of multiple CYP450 enzymes, significantly inhibiting CYP1A2 and to lesser extents CYP3A4, CYP2C19, CYP2C9, and CYP2D6, creating substantial drug interaction potential 5

Common Adverse Effects

• Gastrointestinal side effects are most frequent, with nausea and vomiting being the most common reasons for discontinuation in efficacy studies, though fluvoxamine does not have significantly higher rates than other SSRIs 1, 2, 3, 4, 6
• Sexual dysfunction rates are moderate, with fluvoxamine having lower rates of sexual dysfunction compared to paroxetine, though higher than bupropion 1, 2, 4, 6

Clinical Considerations

• Discontinuation syndrome can occur with fluvoxamine, and it is recommended to taper gradually rather than stopping abruptly 5
• Higher doses of fluvoxamine are not clearly related to greater therapeutic response but are associated with more adverse effects 5